

**Optimizing Patient Outcomes in Bipolar Disorder:  
Long-term Management of Major Depressive Episodes  
Tweeterial #2 References**

**Tweet Five**

Baldessarini RJ, Tondo L, Vázquez GH. Pharmacological treatment of adult bipolar disorder. *Mol psychiatry*. 2019;24(2):198-217. doi:10.1038/s41380-018-0044-2

Citrome L, Tocco M, Zeni C, Pikalov A, Goldman R. Assessing the benefit-risk ratio of approved treatments for bipolar depression using likelihood to be helped or harmed (LHH) analyses. *CNS Spectr*. 2021;26(2):146. doi:10.1017/S109285292000231X

Earley W, Burgess MV, Rekeda L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. *Am J Psychiatry*. 2019;176(6):439-448. doi:10.1176/appi.ajp.2018.18070824

Jahan S. the dilemma, conversion disorder or stiff person syndrome, a case report. *CNS Spectr*. 2021;26(2):145-146. doi:10.1017/S1092852920002308

LATUDA® (lurasidone hydrochloride) [prescribing information]. Sunovion Pharmaceuticals Inc. Revised December 2019. <https://www.latuda.com/LatudaPrescribingInformation.pdf>

McIntyre RS, Calabrese JR. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. *Curr Med Res Opin*. 2019;35(11):1993-2005. doi:10.1080/03007995.2019.1636017

Ragugett RM, McIntyre RS. Cariprazine for the treatment of bipolar depression: a review. *Expert Rev Neurother*. 2019;19(4):317-323. doi:10.1080/14737175.2019.1580571

Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. *Pharmacopsychiatry*. 2014;47(2):43-52. doi:10.1055/s-0033-1363258

SEROQUEL® (quetiapine fumarate) [prescribing information]. AstraZeneca Pharmaceuticals LP. Revised November 2009. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/020639s045s046lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020639s045s046lbl.pdf)

SEROQUEL XR® (quetiapine fumarate) [prescribing information]. AstraZeneca Pharmaceuticals LP. Revised November 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/022047s033s037lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022047s033s037lbl.pdf)

SYMBYAX® (olanzapine and fluoxetine hydrochloride) [prescribing information]. Eli Lilly and Company. Revised 2009. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/021520s022lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021520s022lbl.pdf)

Vraylar® (cariprazine) [prescribing information]. Actavis Pharma, Inc. Revised September 2015. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2015/204370lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf)

### **Tweet Six**

Citrome L. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract.* 2019;73(10):e13397

### **Tweet Seven**

American Psychiatric Association. Bipolar disorder. In: *Diagnostic and Statistical Manual of Mental Disorders: DSM-5.* 5<sup>th</sup> ed. American Psychiatric Association Publishing: Washington, DC; 2013:123-154.

Butler M, Urosevic S, Desai P, et al. *Treatment of Bipolar Disorder in Adults: A Systematic Review.* Rockville, MD: Agency for Healthcare Research and Quality, US Dept of Health and Human Services; 2018. Comparative Effectiveness Review 208.

Malhi GS, Basset D, Boyce R, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry.* 2015;49(12):1087-1206. doi:10.1177/0004867415617657

### **Tweet Nine**

Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. *World J Biol Psychiatry.* 2018;19(8):586-601. doi:10.1080/15622975.2017.1285050

### **Tweet Eleven**

Stahl SM, Morrissette DA, Faedda G, et al. Guidelines for the recognition and management of mixed depression. *CNS Spectr.* 2017;22(2):203-219. doi:10.1017/S1092852917000165

## **Glossary**

CANMAT, Canadian Network for Mood and Anxiety Treatments

ER, extended release

EPS, extrapyramidal side effects

ERC, extended-release capsules

FDA, Food & Drug Administration

IR, immediate release

ISBD, International Society for Bipolar Disorders

LAI, long-acting injectable

MADRS, Montgomery-Asberg Depression Rating Scale

MDE, major depressive episodes

NNT, number needed to treat

SGAs, second-generation antipsychotics

Tx, treatment

w/, with

XR, extended release